The best predictor of response to ICS/OCS in patients with airway diseases, not only asthma, but also COPD and chronic cough of eosinophilic bronchitis, is the presence of eosinophils into the bronchial tissue, which is also predictive of response to therapies that indirectly target eosinophils such as anti-(IL-5) monoclonal antibodies [33, 34]. The gene discussed is IL5; the disease is asthma.